Technical Analysis for BRTX - Biorestorative Therapies Inc

Grade Last Price % Change Price Change
D 0.0096 -3.03% -0.0003
BRTX closed down 3.03 percent on Friday, January 22, 2021, on 54 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Up
Historical BRTX trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Upper Bollinger Band Walk Strength -3.03%
Wide Bands Range Expansion -3.03%
Upper Bollinger Band Touch Strength -3.03%
Upper Bollinger Band Walk Strength -12.73%
Wide Bands Range Expansion -12.73%
Older End-of-Day Signals for BRTX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Biorestorative Therapies Inc Description

BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition


Sector: Other
Industry: Other
Keywords: Biotechnology Biology Life Sciences Surgery Pain Stem Cells Cell Biology Therapeutic Product Cell Therapy Spine Food And Drug Administration Obesity Therapeutic Products Endocrine System Skeletal System Bone Marrow Back Pain Pfizer Metabolic Disorders Adult Stem Cell Adipose Tissue Mesenchymal Stem Cell Rtx Invasive Procedure Invasive Procedures Surgical Treatment Therapeutic Brtx 100to Curved Needle Device Disc/Spine Disease Investigational Curved Needle Device Non Surgical Treatment Painful Lumbosacral Disc Disorders Rohto Pharmaceutical The University Of Pennsylvania Tissue Protocols Treatment Of Disc/Spine Disease Treatment Of Painful Lumbosacral Disc Disorders University Of Pennsylvania

Is BRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.0331
52 Week Low 0.0047
Average Volume 49,422,643
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0084
10-Day Moving Average 0.0095
Average True Range 0.0025
ADX 27.01
+DI 29.2754
-DI 15.6522
Chandelier Exit (Long, 3 ATRs ) 0.0105
Chandelier Exit (Short, 3 ATRs ) 0.0122
Upper Bollinger Band 0.0118
Lower Bollinger Band 0.0050
Percent B (%b) 0.68
BandWidth 80.9524
MACD Line -0.0002
MACD Signal Line -0.0007
MACD Histogram 0.0005
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0113
Resistance 3 (R3) 0.0113 0.0107 0.0110
Resistance 2 (R2) 0.0107 0.0103 0.0107 0.0109
Resistance 1 (R1) 0.0102 0.0101 0.0105 0.0102 0.0108
Pivot Point 0.0096 0.0096 0.0098 0.0096 0.0096
Support 1 (S1) 0.0091 0.0092 0.0094 0.0091 0.0084
Support 2 (S2) 0.0085 0.0090 0.0085 0.0083
Support 3 (S3) 0.0080 0.0085 0.0082
Support 4 (S4) 0.0080